Rosetta Genomics Ltd
OTC:ROSGQ
Intrinsic Value
Rosetta Genomics Ltd. provides therapeutic, diagnostic product development and medical research services. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of ROSGQ.
Rosetta Genomics Ltd's market capitalization is 29.6k USD.
ROSGQ stock price is 0.0001 USD.
ROSGQ.
ROSGQ. Open DCF Valuation
ROSGQ. Open Relative Valuation
ROSGQ.
ROSGQ has positive Gross Profit for the last twelve months.
ROSGQ's long-term assets (6m USD) exceed its long-term liabilties (5m USD).
ROSGQ's ROE (Return on Equity) has significantly increased in the last 3 years from -1 218% to -195%, and is approaching profitability.
ROSGQ's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -442% to -265%, and is approaching profitability.
ROSGQ's short-term assets (6m USD) exceed its short-term liabilties (3m USD).
ROSGQ has negative Operating Income for the last twelve months.
ROSGQ has negative Net Income for the last twelve months.
ROSGQ's ROE (Return on Equity) for the past 12 months is negative and is equal to -195%.
ROSGQ's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -265%.
ROSGQ has negative Free Cash Flow for the last twelve months.
ROSGQ's D/E (Debt to Equity) is very low and is equal to 0.03.
ROSGQ has negative three-year average ROE (Return on Equity): -105%. The company is not efficient at transforming stockholders' equity into net income.
ROSGQ has negative three-year average ROIC (Return on Invested Capital): -14 252%. The company is not efficient at using invested capital to generate operating income.
ROSGQ has negative Net Debt. This means that the company has more cash and short-term investments (1m USD) than debt (37k USD).
ROSGQ's Altman Z-Score is very high and is equal to 39.95.
Fundamental Analysis
Rosetta Genomics Ltd
Balance Sheet Decomposition
Rosetta Genomics Ltd
| Current Assets | 5.7m |
| Cash & Short-Term Investments | 1.3m |
| Receivables | 987k |
| Other Current Assets | 3.4m |
| Non-Current Assets | 527k |
| PP&E | 522k |
| Other Non-Current Assets | 5k |
| Current Liabilities | 2.7m |
| Accounts Payable | 2m |
| Other Current Liabilities | 713k |
| Non-Current Liabilities | 2.4m |
| Long-Term Debt | 37k |
| Other Non-Current Liabilities | 2.4m |
Earnings Waterfall
Rosetta Genomics Ltd
|
Revenue
|
5.8m
USD
|
|
Cost of Revenue
|
-4.9m
USD
|
|
Gross Profit
|
936k
USD
|
|
Operating Expenses
|
-13.7m
USD
|
|
Operating Income
|
-12.8m
USD
|
|
Other Expenses
|
-592k
USD
|
|
Net Income
|
-13.4m
USD
|
Free Cash Flow Analysis
Rosetta Genomics Ltd
What is Free Cash Flow?
ROSGQ Profitability Score
Profitability Due Diligence
Rosetta Genomics Ltd's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
Score
Rosetta Genomics Ltd's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
ROSGQ Solvency Score
Solvency Due Diligence
Rosetta Genomics Ltd's solvency score is 76/100. The higher the solvency score, the more solvent the company is.
Score
Rosetta Genomics Ltd's solvency score is 76/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ROSGQ Price Targets Summary
Rosetta Genomics Ltd
Ownership
ROSGQ Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
ROSGQ Price
Rosetta Genomics Ltd
| Average Annual Return | 258.02% |
| Standard Deviation of Annual Returns | 632.29% |
| Max Drawdown | -100% |
| Market Capitalization | 29.6k USD |
| Shares Outstanding | 296 480 000 |
| Percentage of Shares Shorted | 5.05% |
Company Profile
Rosetta Genomics Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Rosetta Genomics Ltd. provides therapeutic, diagnostic product development and medical research services. The firm is marketing and selling over four diagnostic tests based on its microRNA technologies, which include RosettaGX Cancer Origin, mi-LUNG, mi-KIDNEY and RosettaGX Reveal. The firm's therapeutic pipeline consists of the projects, which include Rimonim Consortium and Magneton Project. The firm focuses on developing diagnostic assay, RosettaGX Reveal V2. The company is also focusing on developing Bladder cancer risk stratification.
You don't have any saved screeners yet
